CTCELLS, Inc.

CTCELLS is a precision oncology company specializing in advanced liquid biopsy diagnostics and innovative immunotherapy development. The company leverages proprietary Circulating Tumor Cell (CTC) isolation technology powered by automated microfluidic systems to enable comprehensive analysis of all CTC types. CTCELLS offers two integrated platforms: (1) CTCeptor, a diagnostic platform for total CTC isolation and characterization, complemented by HyPICC (Hydrogel Pellicle for Lossless Immunocytochemistry) technology achieving >97% cell retention for downstream analysis; and (2) therapeutic development programs including RACE (Receptor Antibody Conjugated Engager) bispecific antibodies and Membrane Bound Protein (MBP)-enhanced natural killer cell therapies. The company's integrated diagnostics-to-therapeutics model enables patient-tailored cancer treatment matching individual tumor characteristics with optimized therapeutic approaches.